IndustryCompany release

Amneal Q3 revenue climbs 10% to $863M as it raises full-year guidance

🇺🇸 Amneal Pharmaceuticals, Inc. (AMRX) · Tue 03 Nov 2026

The US generics and specialty drugmaker swung to a GAAP net loss on Kashiv-related costs, while lifting revenue, adjusted EBITDA and adjusted EPS targets but trimming its cash flow outlook.

Amneal Pharmaceuticals reported results for the third quarter ended 30 September 2026 on 3 November, with revenue up 10% year on year to $863 million.

The company attributed growth to its biosimilars, women's health patches and branded products, naming CREXONT and BREKIYA among the contributors.

Amneal recorded a GAAP net loss of $22 million for the quarter. It linked the loss to acquisition and integration costs connected with Kashiv and to a higher tax provision.

Alongside the results, the company raised its 2026 guidance for revenue, adjusted EBITDA and adjusted EPS. It lowered its outlook for operating cash flow. The summary available does not give the revised guidance ranges or the size of the cash flow reduction.

What it means for your team

  • Biosimilars and branded products are cited as growth drivers, which signals continued emphasis on complex and differentiated portfolios beyond standard generics.
  • Integration costs tied to Kashiv highlight the near-term financial burden of acquisitions, which quality and regulatory teams may feel through site and portfolio integration work.
  • Market-access teams should note the lower operating cash flow outlook alongside higher earnings guidance; detailed figures should be checked in the company's full release.

Company's press release (SEC filing): Amneal Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Amneal Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →